SALEH BAHATI: Open Payments
NPI 1669143145 · TEMPE, AZ. Company-reported industry payments from CMS Open Payments. A payment does not imply wrongdoing.
See the full provider profile for registry, prescribing and billing details.
Industry payments (Sunshine Act)
Source: CMS Open Payments general payments. Payments from drug and device companies are reported by the companies; they do not imply wrongdoing and are separate from Medicare billing.
$5,540 in 44 payments from 12 companies in 2025. Trend: 2023 $72 · 2024 $317 · 2025 $5,540
Consulting: $3,238Food & beverage: $1,610Travel & lodging: $692
| Company | Payments | Amount |
|---|---|---|
| E.R. Squibb & Sons, L.L.C. | 17 | $4,564 |
| Neurocrine BioSciences, Inc. | 5 | $304 |
| Teva Pharmaceuticals USA, Inc. | 4 | $186 |
| ITI, Inc. (d/b/a Intra-Cellular Therapies, Inc.) | 2 | $110 |
| ABBVIE INC. | 4 | $92 |
| Otsuka America Pharmaceutical, Inc. | 3 | $75 |
| Alkermes, Inc. | 2 | $58 |
| Axsome Therapeutics, Inc. | 2 | $48 |
| Janssen Pharmaceuticals, Inc | 2 | $42 |
| Lundbeck LLC | 1 | $30 |
Products named: COBENFY, INGREZZA, AUSTEDO XR, CAPLYTA, VRAYLAR, LYBALVI, ABILIFY MAINTENA, UZEDY.
Industry payments across AZ — which companies pay providers there.
